Patrick Z. Liu

Patrick Z. Liu

Auto-generated profile, based on publicly available information

Patrick Z. Liu

Division of Sleep Medicine, Department of Medicine, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
PLPatrick Z. Liu
Patrick Z. Liu
RNRobin Nusslock
Robin Nusslock
Exercise is known to have numerous neuroprotective and cognitive benefits, especially pertaining to memory and learning related processes. One potential link connecting them is exercise-mediated hippocampal neurogenesis, in which new neurons are generated and incorporated into hippocampal circuits. The present review synthesizes the extant literature detailing the relationship between exercise and hippocampal neurogenesis, and identifies a key molecule mediating this process, brain-derived neurotrophic factor (BDNF). As a member of the neurotrophin family, BDNF regulates many of the processes within neurogenesis, such as differentiation and survival. Although much more is known about the direct role that exercise and BDNF have on hippocampal neurogenesis in rodents, their corresponding cognitive benefits in humans will also be discussed. Specifically, what is known about exercise-mediated hippocampal neurogenesis will be presented as it relates to BDNF to highlight the critical role that it plays. Due to the inaccessibility of the human brain, much less is known about the role BDNF plays in human hippocampal neurogenesis. Limitations and future areas of research with regards to human neurogenesis will thus be discussed, including indirect measures of neurogenesis and single nucleotide polymorphisms within the BDNF gene.

19 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
HRH. Olof Rorsman
H. Olof Rorsman
MMMax A. Müller
Max A. Müller
PLPatrick Z. Liu
Patrick Z. Liu
LSLaura Garmendia Sanchez
Laura Garmendia Sanchez
AKAnissa Kempf
Anissa Kempf
GMGero Miesenböck
Gero Miesenböck
Voltage-gated potassium (KV) channels contain cytoplasmically exposed β-subunits1–5 whose aldo-keto reductase activity6–8 is required for the homeostatic regulation of sleep9. Here we show that Hyperkinetic, the β-subunit of the KV1 channel Shaker in Drosophila 7, forms a dynamic lipid peroxidation memory. Information is stored in the oxidation state of Hyperkinetic’s nicotinamide adenine dinucleotide phosphate (NADPH) cofactor, which changes when lipid-derived carbonyls10–13, such as 4-oxo-2-nonenal or an endogenous analogue generated by illuminating a membrane-bound photosensitizer9,14, abstract an electron pair. NADP+ remains locked in the active site of KVβ until membrane depolarization permits its release and replacement with NADPH. Sleep-inducing neurons15–17 use this voltage-gated oxidoreductase cycle to encode their recent lipid peroxidation history in the collective binary states of their KVβ subunits; this biochemical memory influences—and is erased by—spike discharges driving sleep. The presence of a lipid peroxidation sensor at the core of homeostatic sleep control16,17 suggests that sleep protects neuronal membranes against oxidative damage. Indeed, brain phospholipids are depleted of vulnerable polyunsaturated fatty acyl chains after enforced waking, and slowing the removal of their carbonylic breakdown products increases the demand for sleep.

1 January 2018 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
PLPatrick Z Liu
Patrick Z Liu
RNRobin Nusslock
Robin Nusslock
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China

23 October 2024 in SLEEP
Verified
Journal Article
Closed access
PDF file
PLPatrick Z Liu
Patrick Z Liu
DRDavid M Raizen
David M Raizen
CSCarsten Skarke
Carsten Skarke
TBThomas G Brooks
Thomas G Brooks
RARon C Anafi
Ron C Anafi
The diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (CFS) is based on a constellation of symptoms which center around fatigue. However, fatigue is commonly reported in the general population by people without CFS. Does the biology underlying fatigue in patients with CFS also drive fatigue experienced by individuals without CFS? We used UK Biobank actigraphy data to characterize differences in physical activity patterns and daily temperature rhythms between participants diagnosed with CFS compared to controls. We then tested if single nucleotide variants (SNVs) previously associated with CFS are also associated with the variation of these actigraphic CFS correlates and/or subjective fatigue symptoms in the general population. Participants diagnosed with CFS (n = 295) had significantly decreased overall movement (Cohen’s d = 0.220, 95% CI of -0.335 to -0.106, p-value = 2.42x10-15), lower activity amplitudes (Cohen’s d = -0.377, 95% CI of -0.492 to -0.262, p-value = 1.74x10-6), and lower wrist temperature amplitudes (Cohen’s d = -0.173, 95% CI of -0.288 -0.059, p-value = 0.002) compared to controls (n = 63,133). Of 30 tested SNVs associated in the literature with CFS, one was associated in the control population with subjective fatigue and one with actigraphic measurements (FDR < 0.05). The genetic overlap of CFS risk with actigraphy and subjective fatigue phenotypes suggests that some biological mechanisms underlying pathologic fatigue in CFS patients also underlie fatigue symptoms at a broader population level. Therefore, understanding the biology of fatigue in general may inform our understanding of CFS pathophysiology.

26 May 2026 in Journal of Sleep Research
Verified
Journal Article
Open access
AZAmber J. Zimmerman
Amber J. Zimmerman
PLPatrick Z. Liu
Patrick Z. Liu
BKBrendan T. Keenan
Brendan T. Keenan
TBThomas G. Brooks
Thomas G. Brooks
SGStruan F. A. Grant
Struan F. A. Grant
APAllan I. Pack
Allan I. Pack
How phenotypes are measured, especially when relying on subjective reports, is an impediment to the utility of genome‐wide association studies (GWAS). This is a common problem in GWAS for sleep traits, as many sleep disturbances appear subjectively similar despite having distinct underlying pathophysiology. Phenotype refinement is, therefore, necessary to improve our understanding of complex trait biology. Here, we utilise expanded questionnaire data collected from ~180,000 participants in the UK Biobank to help further distinguish insomnia from restless legs syndrome (RLS) from subjective reports. We demonstrate prior GWAS efforts for insomnia likely mischaracterised participants using a single‐question approach. Through statistical models, we examine two of the most significant GWAS signals for insomnia, namely at the MEIS1 and BTBD9 loci , finding their effects are largely or completely, driven by their effects on RLS. Collectively, our results underscore the necessity of improving phenotype classification and highlight the utility of newly released UK Biobank data for sleep research.

1 August 2025 in Neurology Clinical Practice
Verified
Journal Article
Closed access
CEColin A. Ellis
Colin A. Ellis
PLPatrick Z. Liu
Patrick Z. Liu
ANAlan Napole
Alan Napole
LDLydia Denison
Lydia Denison
NSNoor Fathima Shaik
Noor Fathima Shaik
DXDenise J. Xu
Denise J. Xu
Sleep is a critical component of health and recovery. Awakening sleeping patients for routine vital sign monitoring overnight is a common inpatient practice, but its benefits are uncertain. This study asked 3 questions: (1) How often are routine overnight vital signs abnormal? (2) How often are those abnormal vital signs clinically actionable? (3) Are there patients who may not need routine overnight vital sign monitoring? We analyzed observational retrospective data extracted from electronic health records of patients admitted to inpatient neurology floors at our institution between 2017 and 2024. We defined routine vital signs as collected by nursing assistants at least 3 hours apart. The outcome measure was an urgent clinical action (stat orders, rapid responses, or transfers to a higher level of care) within 1 hour of vital sign events. We compared the rate of urgent clinical actions after abnormal vital signs with the base rate of those events after normal vital signs. Statistical analysis used generalized estimating equations to account for repeated measures. We analyzed 102,184 routine vital sign events from 5,569 neurology admissions. In total, 9% of vital sign events were abnormal. The likelihood of urgent clinical actions increased after abnormal vital sign events, compared with after normal vital sign events during the day (4.3% vs 2.4%, odds ratio (OR) 1.8 [1.6-2.1]); at night (2.4% vs 0.9%, OR 2.8 [2.2-3.7]); during the night in low-risk patients with normal daytime vitals (2.0% vs 0.7%, OR 3.0 [1.8-4.9]); and at night in high-risk patients with abnormal daytime vitals (2.6% vs 1.1%, OR 2.5 [1.7-3.6]). The number needed to treat (NNT), i.e., the number of vital sign events needed to initiate 1 extra urgent clinical action above the base rate, was 1,856 [943; 4,598] in low-risk patients. The NNT for low-risk stroke patients was 1,570 [679; 4,707] and for general neurology patients was 2,231 [797; 5,423]. Urgent clinical actions attributable to abnormal routine vital signs were uncommon in neurology inpatients, especially overnight in patients with normal daytime vital signs. Determining the risks and benefits of routine overnight vital sign monitoring will help hospitals and health care providers move toward more patient-centered inpatient neurologic care.